Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir ± Ribavirin for 12 weeks in 213 HIV-HCV genotype 1 patients. Data on efficacy and tolerability of this strategy in HIV patients have been reported until now only in 43 non cirrhotic HIV subjects.
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program / Teti, E., Ricciardi, A., Antinori, A., Galli, M., Rizzardini, G., Di Biagio, A., Angarano, G., Bruno, R., Mussini, C., De Luca, A., Cattelan, A., Lazzarin, A., Taliani, G., D’Arminio Monforte, A., Mastroianni, C.M., Di Perri, G., Maggiolo, F., Puoti, M., Castelli, F., Gori, A., et al.. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - STAMPA. - 64:Suppl 2(2016), pp. S763-S763. (EASL International Liver Congress Barcelona, SPAIN APR 13-17, 2016) [10.1016/S0168-8278(16)01487-2].
Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection. Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program
Taliani, G.;Mastroianni, C. M.;Vullo, V.;Pennica, A.;Pasquazzi, C.;
2016
Abstract
Background and Aims: An HCV cure is now possible in a large proportion of HIV-HCV patient. We present real life results of a compassionate use program promoted by SIMIT (Infectious and Tropical Diseases Italian Society) of Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir ± Ribavirin for 12 weeks in 213 HIV-HCV genotype 1 patients. Data on efficacy and tolerability of this strategy in HIV patients have been reported until now only in 43 non cirrhotic HIV subjects.| File | Dimensione | Formato | |
|---|---|---|---|
|
Teti_Dasabuvir_2016.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
51.96 kB
Formato
Adobe PDF
|
51.96 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
